Ignite Creation Date:
2024-05-06 @ 3:45 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04748705
Status:
COMPLETED
Last Update Posted:
2022-09-27
First Post:
2021-02-05
Brief Title:
Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of HSV-1
Sponsor:
Virios Therapeutics Inc
Organization:
Virios Therapeutics Inc
Study Overview
Official Title:
A Double-Blinded Randomized Placebo-Controlled Phase 2B Trial of IMC-1 for the Treatment of Fibromyalgia
Status:
COMPLETED
Status Verified Date:
2022-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FORTRESS
Brief Summary:
Randomized double-blind placebo-controlled 16-week study designed to explore the safety and efficacy of IMC-1 for the treatment of patients with fibromyalgia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None